The transgenic mouse model here used was particularly suited for this purpose as it encoded the human C variant of the human ataxin-3 transgene sequence that is present in 70% of the MJD patients, which allowed allele-specific gene silencing. Here, ATXN3 is linked to Spinocerebellar ataxia type 3.